Veradermics (NYSE:MANE) Posts Earnings Results, Meets Estimates

Veradermics (NYSE:MANE) issued its quarterly earnings data on Tuesday. The company reported ($0.58) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.58), FiscalAI reports.

Veradermics Trading Up 2.3%

MANE stock traded up $2.48 during midday trading on Wednesday, hitting $111.43. The stock had a trading volume of 369,525 shares, compared to its average volume of 591,639. The company’s fifty day moving average price is $109.05. The firm has a market cap of $4.66 billion and a price-to-earnings ratio of -83.76. Veradermics has a 1-year low of $32.00 and a 1-year high of $131.24.

Wall Street Analyst Weigh In

MANE has been the topic of several recent research reports. Needham & Company LLC lifted their target price on shares of Veradermics from $136.00 to $164.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen raised Veradermics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Leerink Partners increased their price target on Veradermics from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. UBS Group set a $170.00 price objective on shares of Veradermics in a research report on Wednesday, July 15th. Finally, Weiss Ratings assumed coverage on shares of Veradermics in a research report on Tuesday, May 26th. They issued a “sell (d+)” rating on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $153.00.

Veradermics Company Profile

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.